
Semax
Russian nootropic with an ACTH-fragment structure and a domestic clinical literature in stroke recovery.
Most of the clinical literature is Russian-language. Translation quality varies.
General profile
- Class
- Cognitive
- Evidence
- Mixed or moderate evidence
- Studied dose range
- 300–600 mcg
- Frequency in protocols
- Daily
- Route
- Intranasal in most studies
- Half life
- Minutes (metabolite active)
- Reconstitution
- Supplied as solution in most research literature
- Storage
- Refrigerated
Timing and cycling in the literature
Usually dosed in the morning window
Daily, usually intranasal
Stimulating and alerting in the published work. Late-day dosing is a common cause of self-reported insomnia.
Reported cycle: 2 weeks on, 2 weeks off
The Russian clinical use is short courses of ten to fourteen days, repeated with gaps.
Watch for: Irritability, insomnia when dosed late, and blood pressure if you already run high.
What it conflicts with
Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.
- Hard stopBody level hard stop
Semax + Methylene blue and any serotonergic drug
Do not run with methylene blue or serotonergic medication
Methylene blue inhibits MAO-A. Stacked with serotonin-raising agents (SSRIs, SNRIs, MAOIs, tricyclics, tramadol, St John's Wort) the risk is serotonin syndrome. Timing does not fix this one, it is a mechanism conflict.
- Separate syringesTiming
Semax + DSIP
Opposite ends of the day, minimum 8 hours
One is studied for sedation and slow-wave sleep, the other for alertness. Co-administering them cancels the observable effect of both and tells you nothing.
- Pick oneRedundant, pick one
Semax + Adamax
Same target hit twice
Adamax is a modified Semax, not a second mechanism.
- Pick oneRedundant, pick one
Semax + P-21
Same target hit twice
Overlapping Semax-family signalling. Introduce one, hold it, then judge.
- Pick oneTiming
Semax + Selank
Commonly paired, still start separately
The Russian literature pairs an anxiolytic with a stimulating analog and reports no interaction. Introduce them a week apart so you know which one is doing what.
Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.
See how Semax fits your week
The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.
Model this in the injection schedulerThe studies
Human trials: Russian trials, largely unreplicated in Western literature.
Open questions: Reporting standards make independent appraisal difficult.
Published papers
Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.
- SIRT1/AMPK/PGC1α pathway in ischemic stroke: Elucidating neuroprotective strategies (Review)
Mol Med Rep · 2026 · Review. Abbasi IN, Amin N, Xu Q, Hussain AB, Wu F, Yuan X, Yang Y, Ye S, Fang M, Jiang Y.
- Molecular regulation of PGC-1α: from protein-protein interactions and post-translational modifications to pharmacological modulation
J Mol Med (Berl) · 2026 · Review. Rios WQ, Silva CM, Ferreira R, Gomes JRB.
- Multi-Layer Magnetic Shields Based on Fe-Based Nanocrystalline and Co-Based Amorphous Ribbons
Materials (Basel) · 2026. Liang Y, Liu B, Ma H, Pan L, He A, Dong Y, Man Q, Li J.
- Measuring the Time-Scale-Dependent Information Flow Between Maternal and Fetal Heartbeats During the Third Trimester: Impact of Fetal Sex and Maternal Chronic Stress
Biology (Basel) · 2026. Garnier NB, Molinet MS, Antonelli MC, Lobmaier SM, Frasch MG.
- Semi-Mechanistic PK/PD Modeling of Platelets and Spleen Volume With Navitoclax in Combination With Ruxolitinib in Patients With Myelofibrosis
CPT Pharmacometrics Syst Pharmacol · 2026. Polepally AR, Goebel A, Patel M, Biesdorf C, Potluri J, Menon RM, Mensing S, Engelhardt B.
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Int J Mol Sci · 2026 · Review. Renke G, Chinellato L.
- Digitally Guided Hybrid Maxillary Expansion with Supragingival Mandibular Miniplates for Class III Correction in Late Adolescents: A Pilot Clinical Study
J Clin Med · 2026. Arcos I, Walter A, Marc T, Clusellas N, Puigdollers A.
- Protein-Driven Copper Redox Regulation: Uncovering the Role of Disulphide Bonds and Allosteric Modulation
Angew Chem Int Ed Engl · 2026. Sternke-Hoffmann R, Liu C, Wang X, Pupart H, Sun X, Dreiser JG, Palumaa P, Liao Q, Krack M, Luo J.
- [Effect of a combined physiotherapeutic approach on changes in functional parameters after endovitreal surgery of rhegmatogenous retinal detachment with a favorable anatomical outcome]
Vestn Oftalmol · 2026. Sheludchenko VM, Matyushchenko AG, Alharki L, Baryshev KV, Balkar SS, Makarova MA, Alenov MM, Harki YA.
- Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Front Aging · 2026 · Review. Mavrych V, Shypilova I, Bolgova O.
Search the full literature
- PubMed: all indexed papers
Every indexed paper, newest first. Filter to Clinical Trial or Review in the sidebar.
- PubMed: human clinical trials only
The honest test of an evidence claim. An empty result is itself an answer.
- ClinicalTrials.gov registrations
Registered, ongoing and completed trials, including ones that never published.
- Europe PMC full text
Often surfaces open-access full text that PubMed only abstracts.